Clinical Trial Update: Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD) [Phase 3]

View source ↗

Summary

Phase 3 long-term safety data show rivastigmine capsules and patches were generally well tolerated in patients with Parkinson's disease dementia over extended u…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease Dementia

Drugs mentioned

• Rivastigmine Capsule (Rivastigmine)
• Rivastigmine Patch (Rivastigmine)

Snippet

Sponsor: Novartis | Conditions: Parkinson's Disease Dementia | Phase 3 | Status: COMPLETED | Results posted: 2011-11-28